期刊文献+

4种配比的头孢曲松/他唑巴坦的体外抗菌活性 被引量:6

Antibacterial activities of different matching ratios of Ceftriaxone and Tazobactam in vitro
下载PDF
导出
摘要 目的研究4种配比头孢曲松/他唑巴坦(CRO/TAZ)及头孢曲松(CRO)单剂对四川地区临床分离致病菌的体外抗菌活性。方法测定525株临床分离致病菌的最低仰菌浓度(MIC)最低杀菌浓度(MBC);采用活菌计数法绘制杀菌曲线;并观察细菌接种量、培养基pH和血清蛋白含量对体外抗菌活性的影响。结果4种配比CRO/TAZ对甲氧西材耐药金菊菌和表皮葡萄球功的MIC50为1~8 mg.L-1,是CRO单剂的1/32~1/256;对产ESBLs大肠埃希菌和肺炎克雷伯菌的MIC50分别降低了8~32倍和16~64倍,MIC90降低了8倍以上;CRO/TAZ(6:1)体外抗菌作用优于头孢哌酮钠-他唑巴坦钠(4:1)或相当;但优于哌拉西林钠-他唑巴坦钠(8:1);4种配比CRO/TAZ均具有很强的杀菌作用,明显优于CRO单剂。结论4种配比CRO/CAZ对大多数临床分离的致病菌均有较强的体外抗菌活性,明显高于单剂。其中,6:1为较合理的配方。 OBJECTIVE To study the antibacterial activities of ceftriaxone and Ceftriaxone/Tazobactam(CRO/TAZ) against clinically isolated pathogenic bacteria from Sichuan area in vitro.METHODSMinimal inhibitory concentrations(MIC) and minimal bactericidal concentrations(MBC) were determined on 525 clinically isolated pathogenic bacteria.Killing curve was drawn by determination of colony forming unit counts at each time interval.The influences of the inoculum size,pH and concentration of serum protein on antibacterial ...
出处 《华西药学杂志》 CAS CSCD 北大核心 2008年第2期143-146,共4页 West China Journal of Pharmaceutical Sciences
关键词 头孢曲松 他唑巴坦 体外抗菌活性 Β-内酰胺酶 Ceftriaxone Tazobactam In vitro antibacterial activity β-Lactamase
  • 相关文献

参考文献4

  • 1[1]Rotschafe JC,Ostergaas BE.Combination β-lactam and lacta mase-inhibitor products:amimic-robial activity and efficiency of enzyme inhibition[J].Am J Heatth-Syst Pharm,1995,52:15-23.
  • 2朱延军,胡军.一种新型β-内酰胺酶抑制剂─—他佐巴坦[J].国外医药(合成药.生化药.制剂分册),1999,20(5):297-300. 被引量:13
  • 3[3]Lister PD,Prevan AM,Sanden CC.Importance of beta-lactamase inhibitor phamacokinetics in the phamavodynamies of inhivitordrug combinations:studies with piperaeillin-tazobactam and piperacillin-sulbactam[J].Antimic Agents Chemother,1997,41:721-727.
  • 4[4]National Committee for Clinical Labarotory Stanch.Performance standards for antimicrobial susceptibility testing ninth informational supplement[M].NCCLS documents,2000.17-99.

二级参考文献3

共引文献12

同被引文献60

引证文献6

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部